Pan-cancer characterization of receptor tyrosine kinases alterations to sort targetable drivers from passengers

被引：0
|
作者：
Vanacker, H. [1 ]
Attignon, V. K. [2 ]
Brahmi, M. [1 ]
Dufresne, A. [1 ]
Cassier, P. [1 ]
Carbonnaux, M. [3 ]
Pissaloux, D. [2 ]
Boyault, S. [2 ]
Wang, Q. L. [2 ]
Tredan, O. [1 ]
Tirode, F. [2 ]
Blay, J-Y [1 ]
机构：
[1] Ctr Leon Berard, Med Oncol Dept, Lyon, France
[2] Ctr Leon Berard, Translat Res Dept, Lyon, France
[3] CH Annecy Gennevois, Oncol Dept, Epagny Metz Tessy, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 08期
关键词：
D O I：
10.1016/j.annonc.2022.09.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1385 / S1385
页数：1
相关论文
共 25 条
  • [1] The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
    Disel, Umut
    Madison, Russell
    Abhishek, Kumar
    Chung, Jon H.
    Trabucco, Sally E.
    Matos, Asli O.
    Frampton, Garrett M.
    Albacker, Lee A.
    Reddy, Venkataprasanth
    Karadurmus, Nuri
    Benson, Adam
    Webster, Jennifer
    Paydas, Semra
    Cabanillas, Ruben
    Nangia, Chaitali
    Ozturk, M. A.
    Millis, Sherri Z.
    Pal, Sumanta K.
    Wilky, Breelyn
    Sokol, Ethan S.
    Gay, Laurie M.
    Soman, Salil
    Ganesan, Shridar
    Janeway, Katherine
    Stephens, Phil J.
    Zhu, Viola W.
    Ou, Sai-Hong Ignatius
    Lovly, Christine M.
    Gounder, Mrinal
    Schrock, Alexa B.
    Ross, Jeffrey S.
    Miller, Vincent A.
    Klempner, Samuel J.
    Ali, Siraj M.
    ONCOLOGIST, 2020, 25 (01): : E39 - E47
  • [2] Comprehensive pan-cancer analysis of KRAS genomic alterations (GA) including potentially targetable subsets
    Ou, S. -H. I.
    Sokol, E. S.
    Madison, R.
    Chung, J.
    Ross, J. S.
    Miller, V. A.
    Alexander, B. M.
    Ali, S. M.
    Schrock, A. B.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 26 - 26
  • [3] Pan-cancer clinical impact of latent drivers from double mutations
    Bengi Ruken Yavuz
    Chung-Jung Tsai
    Ruth Nussinov
    Nurcan Tuncbag
    Communications Biology, 6
  • [4] Pan-cancer clinical impact of latent drivers from double mutations
    Yavuz, Bengi Ruken
    Tsai, Chung-Jung
    Nussinov, Ruth
    Tuncbag, Nurcan
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [5] The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer
    Morishita, Asahiro
    Gong, Jian
    Nomura, Takako
    Yoshida, Hirohito
    Izuishi, Kunihiko
    Suzuki, Yasuyuki
    Kushida, Yoshio
    Haba, Reiji
    D'Armientoi, Jeanine
    Masaki, Tsutomu
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 37 (04) : 829 - 835
  • [6] Systematic identification of novel functional tumor-specific mutations in receptor tyrosine kinases based on their pan-cancer mutational profiles in Japanese patients with cancer
    Serizawa, Masakuni
    Nagashima, Takeshi
    Shimoda, Yuji
    Ohnami, Shumpei
    Ohnami, Sumiko
    Ohshima, Keiichi
    Mochizuki, Tohru
    Nakajima, Takashi
    Urakami, Kenichi
    Kusuhara, Masatoshi
    Yamaguchi, Ken
    CANCER RESEARCH, 2017, 77
  • [7] CDX2-Suppressed Colorectal Cancers Possess Potentially Targetable Alterations in Receptor Tyrosine Kinases and Other Colorectal-Cancer-Associated Pathways
    Voutsadakis, Ioannis A.
    DISEASES, 2024, 12 (10)
  • [8] Mutation of neurotrophic tyrosine receptor kinase can promote pan-cancer immunity and the efficacy of immunotherapy
    Wang, Congren
    Li, Yingying
    Huang, Jinyuan
    Yan, Huimeng
    Zhao, Bin
    MOLECULAR CANCER, 2024, 23 (01)
  • [9] Receptor tyrosine kinases in cancer escape from BRAF inhibitors
    Lo, Roger S.
    CELL RESEARCH, 2012, 22 (06) : 945 - 947
  • [10] Receptor tyrosine kinases in cancer escape from BRAF inhibitors
    Roger S Lo
    Cell Research, 2012, 22 : 945 - 947
123